[1]杨振宇 方伟 任何 胡健强 马文帅 王秋和 李妍.经导管主动脉瓣置换术后生物瓣功能障碍的研究进展[J].心血管病学进展,2024,(8):690.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.005]
　YANG Zhenyu,FANG Wei,REN He,et al.Research Progress of Bioprosthetic Valve Dysfunction After?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2024,(8):690.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.005]
点击复制

经导管主动脉瓣置换术后生物瓣功能障碍的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年8期
页码:
690
栏目:
综述
出版日期:
2024-08-25

文章信息/Info

Title:
Research Progress of Bioprosthetic Valve Dysfunction After?ranscatheter Aortic Valve Replacement
作者:
杨振宇 方伟 任何 胡健强 马文帅 王秋和 李妍
(空军军医大学唐都医院心血管内科,陕西 西安710038)
Author(s):
YANG Zhenyu; FANG Wei; REN He; HU Jianqiang; MA Wenshuai; WANG Qiuhe; LI Yan
?Department of Cardiology,Tangdu Hospital,Air Force Military Medical University,Xi ’an 710038,Shaanxi,China)
关键词:
主动脉瓣狭窄; 经导管主动脉瓣置换术; 生物瓣功能障碍; 耐久性
Keywords:
Aortic stenosis; Transcatheter aortic valve replacement; Bioprosthetic valve dysfunction; Durability
DOI:
10.16806/j.cnki.issn.1004-3934.2024.08.005
摘要:
经导管主动脉瓣置换术（TAVR）已成为治疗主动脉瓣狭窄的重要介入手段，得益于材料技术的进步与操作经验的积累，TAVR已广泛运用于外科手术中高风险的患者，并逐渐向年轻、低风险患者拓展。生物瓣作为TAVR的核心材料，其功能障碍可能影响手术效果和患者的生活质量。现对生物瓣功能障碍的诊断评估、危险因素、临床预后和相关研究成果进行总结，旨在为预防和减轻生物瓣功能障碍、提高生物瓣的耐久性提供参考。
Abstract:
Transcatheter aortic valve replacement （TAVR） is an important intervention for patients with aortic stenosis. Thanks to the advancement of material technology and the accumulation of operational experience,TAVR has been widely used in high-risk patients and is gradually expanding to younger and low-risk patients. As the core material of TAVR,the dysfunction of bioprosthetic valve may reduce treatment efficacy and patient quality of life. This review comprehensively summarizes the diagnosis and prognosis of bioprosthetic valve dysfunction,providing reference for preventing and reducing biological valve dysfunction and improving the durability of bioprosthetic valves

参考文献/References:

[1] Davidson LJ,Davidson CJ. Transcatheter treatment of valvular heart disease:a review[J]. JAMA,2021,325(24):2480-2494.?div>[2] Sharma T,Krishnan AM,Lahoud R,et al. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis[J]. J Am Coll Cardiol,2022,80(21):2054-2056.?/div>

[3] Arsalan M,Walther T. Durability of prostheses for transcatheter aortic valve implantation[J]. Nat Rev Cardiol,2016,13(6):360-367.?/div>
[4] Salaun E,Clavel MA,Rodés-Cabau J,et al. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation[J]. Heart,2018,104(16):1323-1332.?/div>
[5] Généreux P,Piazza N,Alu MC,et al. Valve Academic Research Consortium 3:updated endpoint definitions for aortic valve clinical research[J]. Eur Heart J,2021,42(19):1825-1857.?/div>
[6] Blanke P,Weir-McCall JR,Achenbach S,et al. Computed tomography imaging in the context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR):an expert consensus document of the society of cardiovascular computed tomography[J]. JACC Cardiovasc Imaging,2019,12(1):1-24.?/div>
[7] Pibarot P,Herrmann HC,Wu C,et al. Standardized definitions for bioprosthetic valve dysfunction following aortic or mitral valve replacement:JACC state-of-the-art review[J]. J Am Coll Cardiol,2022,80(5):545-561.?/div>
[8] Capodanno D,Petronio AS,Prendergast B,et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves:a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2017,38(45):3382-3390.?/div>
[9] Dvir D,Bourguignon T,Otto CM,et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves[J]. Circulation,2018,137(4):388-399.
[10] Zoghbi WA,Chambers JB,Dumesnil JG,et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound[J]. J Am Soc Echocardiogr,2009,22(9):975-1014.
[11] Jilaihawi H,Asch FM,Manasse E,et al. Systematic CT methodology for the evaluation of subclinical leaflet?hrombosis[J]. JACC Cardiovasc Imaging,2017,10(4):461-470.
[12] Delgado V,Ajmone Marsan N,de Waha S,et al. 2023 ESC Guidelines for the management of endocarditis[J]. Eur Heart J,2023,44(39):3948-4042.
[13] del Val D,Trottier M,Alperi A,et al. 18F-Fluorodeoxyglucose uptake pattern in noninfected transcatheter aortic valves[J]. Circ Cardiovasc Imaging,2020,13(11):e011749.
[14] ?lc AJ,Línková H,Tou?k P. Transcatheter aortic valve durability,predictors of bioprosthetic valve dysfunction,longer-term outcomes—A review[J]. Expert Rev Med Devices,2024,21(1-2):15-26.
[15] Kostyunin AE,Yuzhalin AE,Rezvova MA,et al. Degeneration of bioprosthetic heart valves:update 2020[J]. J Am Heart Assoc,2020,9(19):e018506.
[16] Schoen FJ,Levy RJ. Calcification of tissue heart valve substitutes:progress toward understanding and prevention[J]. Ann Thorac Surg,2005,79(3):1072-1080.
[17] Arzani A,Mofrad MRK. A strain-based finite element model for calcification progression in aortic valves[J]. J Biomech,2017,65:216-220.
[18] Hioki H,Watanabe Y,Kawashima H,et al. Predictors of bioprosthetic valve dysfunction after transcatheter aortic valve implantation[J]. AsiaIntervention,2023,9(1):87-94.
[19] Pibarot P,Weissman NJ,Stewart WJ,et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis:a PARTNER trial cohort--A analysis[J]. J Am Coll Cardiol,2014,64(13):1323-1334.
[20] Adams DH,Popma JJ,Reardon MJ,et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis[J]. N Engl J Med,2014,370(19):1790-1798.
[21] Ramlawi B,Bedeir K. Overcoming the transcatheter aortic valve replacement Achilles heel:paravalvular leak[J]. Ann Cardiothorac Surg,2020,9(6):499-501.
[22] Fukui M,Bapat VN,Garcia S,et al. Deformation of transcatheter aortic valve prostheses:implications for hypoattenuating leaflet thickening and clinical outcomes[J]. Circulation,2022,146(6):480-493.
[23] Khodaee F,Barakat M,Abbasi M,et al. Incomplete expansion of transcatheter aortic valves is associated with propensity for valve thrombosis[J]. Interact Cardiovasc Thorac Surg,2020,30(1):39-46.
[24] Midha PA,Raghav V,Sharma R,et al. The fluid mechanics of transcatheter heart valve leaflet thrombosis in the neosinus[J]. Circulation,2017,136(17):1598-1609.
[25] Montalescot G,Redheuil A,Vincent F,et al. Apixaban and valve thrombosis after transcatheter aortic valve replacement:the ATLANTIS-4D-CT randomized clinical trial substudy[J]. JACC Cardiovasc Interv,2022,15(18):1794-1804.
[26] Del Val D,Panagides V,Mestres CA,et al. Infective endocarditis after transcatheter aortic valve replacement:JACC state-of-the-art review[J]. J Am Coll Cardiol,2023,81(4):394-412.
[27] Tang G,Zaid S,Kleiman NS,et al. Explant vs redo-TAVR after transcatheter valve failure:mid-term outcomes from the EXPLANTORREDO-TAVR international registry[J]. JACC Cardiovasc Interv,2023,16(8):927-941.
[28] Fukuhara S,Tanaka D,Brescia AA,et al. Aortic valve reintervention in patients with failing transcatheter aortic bioprostheses:a statewide experience[J]. J Thorac Cardiovasc Surg,2023,165(6):2011-2020.
[29] Landes U,Richter I,Danenberg H,et al. Outcomes of redo transcatheter aortic valve replacement according to the initial and subsequent valve type[J]. JACC Cardiovasc Interv,2022,15(15):1543-1554.
[30] Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement in low-risk patients at five years[J]. N Engl J Med,2023,389(21):1949-1960.
[31] Forrest JK,Deeb GM,Yakubov SJ,et al. 4-Year outcomes of patients with aortic stenosis in the Evolut low risk trial[J]. J Am Coll Cardiol,2023,82(22):2163-2165.
[32] Garcia S,Ye J,Webb J,et al. Transcatheter treatment of native aortic valve regurgitation:the North American experience with a novel device[J]. JACC Cardiovasc Interv,2023,16(16):1953-1960.
[33] Huded CP,Allen KB,Chhatriwalla AK. Counterpoint:challenges and limitations of transcatheter aortic valve implantation for aortic regurgitation[J]. Heart,2021,107(24):1942-1945.
[34] Rahmani B,Tzamtzis S,Sheridan R,et al. A new transcatheter heart valve concept (the TRISKELE):feasibility in an acute preclinical model[J]. EuroIntervention,2016,12(7):901.
[35] Singh SK,Kachel M,Castillero E,et al. Polymeric prosthetic heart valves:a review of current technologies and future directions[J]. Front Cardiovasc Med,2023,10:1137827.
[36] Appa H,Park K,Bezuidenhout D,et al. The technological basis of a balloon-expandable TAVR system:non-occlusive deployment,anchorage in the absence of calcification and polymer leaflets[J]. Front Cardiovasc Med,2022,9:791949.
[37] Pibarot P,Ternacle J,Jaber WA,et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial[J]. J Am Coll Cardiol,2020,76(16):1830-1843.
[38] Thyregod HGH,J?gensen TH,Ihlemann N,et al. Transcatheter or surgical aortic valve implantation:10-year outcomes of the NOTION trial[J]. Eur Heart J,2024，45(13):1116-1124.
[39] Okuno T,Tomii D,Lanz J,et al. 5-Year outcomes with self-expanding vs balloon-expandable transcatheter aortic valve replacement in patients with small annuli[J]. JACC Cardiovasc Interv,2023,16(4):429-440.
[40] Abdel-Wahab M,Landt M,Neumann FJ,et al. 5-Year outcomes after TAVR with balloon-expandable versus self-expanding valves:results from the CHOICE randomized clinical trial[J]. JACC Cardiovasc Interv,2020,13(9):1071-1082.
[41] O’Hair D,Yakubov SJ,Grubb KJ,et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk[J]. JAMA Cardiol,2023,8(2):111-119.[42] Didier R,Eltchaninoff H,Donzeau-Gouge P,et al. Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients[J]. Circulation,2018,138(23):2597-2607.

相似文献/References:

[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
　YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(8):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
　XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(8):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
　LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(8):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[4]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
　XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(8):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
　CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
　DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(8):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[7]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
　ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
[8]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
　DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(8):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[9]胡正 陈祥 洲陈静.经导管主动脉瓣置换术后冠状动脉阻塞的研究进展[J].心血管病学进展,2023,(5):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
　HUZheng,CHENXiangzhou,CHENJing.Coronary Occlusion of Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2023,(8):402.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.005]
[10]刘雅靓 张静 苟中山 黄青霞 杨娅.二叶主动脉瓣的分型与临床意义[J].心血管病学进展,2024,(6):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]
　LIU Yaliang,ZHANG Jing,GOU Zhongshan,et al.Classification and Clinical Significance of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2024,(8):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]
[11]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
　YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(8):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[12]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[13]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
　LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[14]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
　WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[15]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
　ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[16]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
　Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(8):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
[17]吴文军 谢玲 李婷婷 丁任重 胡义杰.经导管主动脉瓣置换术围手术期脑卒中和脑保护研究进展[J].心血管病学进展,2024,(4):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
　WU Wenjun,XIE Ling,LI Tingting,et al.Perioperative Transcatheter Aortic Valve Replacement for Stroke and Cerebral Protection[J].Advances in Cardiovascular Diseases,2024,(8):295.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.002]
[18]吴奕璇 邓少东 陈建英.经导管主动脉瓣置换术后瓣周漏相关危险因素研究进展[J].心血管病学进展,2024,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.001]
　WU Yixuan,DENG Shaodong,CHEN Jianying.Risk Factors Related to Perivalvular Leakage After Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2024,(8):481.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.001]
[19]陈道乾 何胜虎.重度主动脉瓣狭窄合并慢性肾脏病患者经导管主动脉瓣置换术研究进展[J].心血管病学进展,2024,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]
　CHEN Daoqian,HE Shenghu.Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis Combined with Chronic Kidney Disease:a Study in Progress[J].Advances in Cardiovascular Diseases,2024,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]

更新日期/Last Update: 2024-09-12